Alkermes plc (ALKS)

Market Cap	7.50B +44.2%
Revenue (ttm)	1.56B +3.2%
Net Income	152.72M -56.7%
EPS	0.91 -56.5%
Shares Out	166.68M
PE Ratio	49.47
Forward PE	26.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,727,743
Open	45.25
Previous Close	44.51
Day's Range	43.98 - 45.76
52-Week Range	25.17 - 45.76
Beta	0.33
Analysts	Buy
Price Target	46.13 (+2.53%)
Earnings Date	Jul 28, 2026

About ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 2,050
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS
• Website: https://www.alkermes.com

Financial Performance

In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.

Analyst Summary

According to 17 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $46.13, which is an increase of 2.53% from the latest price.

Price Target

$46.13

(2.53% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 19, 2026

Data Sources Report a data error